Yukiko Nakajima
University of Tokyo
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Yukiko Nakajima.
European Journal of Clinical Pharmacology | 2005
Yukiko Nakajima; Yoshiro Saito; Kisho Shiseki; Hiromi Fukushima-Uesaka; Ryuichi Hasegawa; Shogo Ozawa; Kenji Sugai; Masaaki Katoh; Osamu Saitoh; Teiichi Ohnuma; Mitsuru Kawai; Taisuke Ohtsuki; Chieko Suzuki; Narihiro Minami; Hideo Kimura; Yu-ichi Goto; Naoyuki Kamatani; Nahoko Kaniwa; Jun-ichi Sawada
ObjectiveMicrosomal epoxide hydrolase (mEH) is an enzyme that detoxifies reactive epoxides and catalyzes the biotransformation of carbamazepine-10,11-epoxide (CBZ-epoxide) to carbamazepine-10,11-diol (CBZ-diol). Utilizing single nucleotide polymorphisms (SNPs) of the EPHX1 gene encoding mEH, we identified the haplotypes of EPHX1 blocks and investigated the association between the block haplotypes and CBZ-epoxide metabolism.Methods SNPs of EPHX1 were analyzed by means of polymerase chain reaction amplification and DNA sequencing using DNA extracted from the blood leukocytes of 96 Japanese epileptic patients, including 58 carbamazepine-administered patients. The plasma concentrations of CBZ and its four metabolites were determined using high-performance liquid chromatography.ResultsFrom sequencing all 9 exons and their surrounding introns, 29 SNPs were found in EPHX1. The SNPs were separated into three blocks on the basis of linkage disequilibrium, and the block haplotype combinations (diplotypes) were assigned. Using plasma CBZ-diol/CBZ-epoxide ratios (diol/epoxide ratios) indicative of the mEH activity, the effects of the diplotypes in each EPHX1 block were analyzed on CBZ-epoxide metabolism. In block 2, the diol/epoxide ratios increased significantly depending on the number of haplotype *2 bearing Y113H (P=0.0241). In block 3, the ratios decreased depending on the number of haplotype *2 bearing H139R (P=0.0351). Also, an increasing effect of a *1 subtype, *1c, was observed on the ratio.ConclusionThese results show that some EPHX1 haplotypes are associated with altered CBZ-epoxide metabolism. This is the first report on the haplotype structures of EPHX1 and their potential in vivo effects.
Cancer Chemotherapy and Pharmacology | 2005
Ayako Yawata; Su-Ryang Kim; Atsuko Miyajima; Takashi Kubo; Seiichi Ishida; Yoshiro Saito; Yukiko Nakajima; Noriko Katori; Yoshiaki Matsumoto; Masamichi Fukuoka; Yasuo Ohno; Shogo Ozawa; Jun-ichi Sawada
Purpose: Thymidylate synthase (TS) is one of the target molecules for the antitumor effects of fluoropyrimidine drugs. The cellular thymidylate synthase level is one of the determining factors for the antitumor activity of fluoropyrimidines. TYMS, which encodes TS, has been reported to possess 28-bp tandem repeat sequences in its 5′-untranslated region, the number of which varies. In addition, single nucleotide polymorphisms have also been shown in a triple repeat sequence. In this study, correlation between the polymorphic tandem repeat sequences of the TYMS gene and the antitumor activities of 5-fluorouracil (5-FU) and 5-fluoro-2′-deoxyuridine (FUdR) were investigated with 30 established human cell lines derived from solid tumors. Methods: A reporter assay system was developed in order to compare the ability of the transactivation mediated by the double (2R) and triple (c- or g-type, 3Rc or 3Rg, respectively) repeat sequences using a human colon cancer cell line, DLD-1. The 50% inhibitory concentration (IC50) of cell growth by 5-FU and FUdR was measured with 30 different established cell lines of human solid tumors. Genotypes based on the number of the 28-bp TYMS tandem repeat for the above cell lines were determined by electrophoretical analysis of PCR products containing the repeat sequences and nucleotide sequencing. Results: The reporter activity mediated by the 3Rg sequence was significantly higher than that by the 2R and 3Rc sequences. Activities mediated by the 2R and 3Rc sequences were comparable. According to the reporter assay, 2R and 3Rc were judged as low TS expression alleles and 3Rg as a high TS expression allele. On the basis of IC50 values, cells possessing the 2R/2R and 2R/3R repeat of TYMS were significantly more sensitive to FUdR than those with the 3R/3R repeat. Cells possessing 3Rg/3Rg (a high TS expression genotype) were significantly less sensitive to FUdR than cells with 2R/2R, 2R/3Rc, and 3Rc/3Rc (low TS expression genotypes). Conclusions: Our results of the reporter assays using 2R, 3Rc, and 3Rg repeat sequences prompted us to classify 3Rg as a high TS expression allele, and 2R and 3Rc as low TS expression alleles. The cells with low TS expression alleles were shown to exhibit significantly higher FUdR sensitivity than the cells with high TS expression alleles for the first time. These results were consistent with numerous previous in vitro and in vivo findings that tumors showing high TS expression were less sensitive to fluoropyrimidines. These results support the idea that genotyping the tandem repeat sequences of TYMS in the 5′-untranslated region is useful for individualized therapy involving fluoropyrimidine antitumor drugs.
Journal of Pharmacology and Experimental Therapeutics | 2003
Norie Murayama; Akiko Soyama; Yoshiro Saito; Yukiko Nakajima; Kazuo Komamura; Kazuyuki Ueno; Shiro Kamakura; Masafumi Kitakaze; Hideo Kimura; Yu-ichi Goto; Osamu Saitoh; Masaaki Katoh; Teiichi Ohnuma; Mitsuru Kawai; Kenji Sugai; Taisuke Ohtsuki; Chieko Suzuki; Narihiro Minami; Shogo Ozawa; Jun-ichi Sawada
Drug Metabolism and Disposition | 2000
Kanji Komatsu; Kiyomi Ito; Yukiko Nakajima; Shin-ichi Kanamitsu; Susumu Imaoka; Yoshihiko Funae; Carol E. Green; Charles A. Tyson; Noriaki Shimada; Yuichi Sugiyama
Biological & Pharmaceutical Bulletin | 1996
Shuji Shimada; Yukiko Nakajima; Koujirou Yamamoto; Yasufumi Sawada; Tatsuji Iga
Drug Metabolism and Pharmacokinetics | 2002
Satoru Koyano; Kouichi Kurose; Shogo Ozawa; Mayumi Saeki; Yukiko Nakajima; Ryuichi Hasegawa; Kazuo Komamura; Kazuyuki Ueno; Shiro Kamakura; Toshiharu Nakajima; Hirohisa Saito; Hideo Kimura; Yu-ichi Goto; Osamu Saitoh; Masaaki Katoh; Teiichi Ohnuma; Mitsuru Kawai; Kenji Sugai; Taisuke Ohtsuki; Chieko Suzuki; Narihiro Minami; Yoshiro Saito; Jun-ichi Sawada
Biological & Pharmaceutical Bulletin | 2000
Yukiko Nakajima; Kenji Hattori; Machiko Shinsei; Noriko Matsunaga; Hisashi Iizasa; Hiroyuki Sasabe; Hitoshi Akiyama; Gohachiro Miyamoto; Emi Nakashima
Biological & Pharmaceutical Bulletin | 1996
Yukiko Nakajima; Koujirou Yamamoto; Yasuhiko Yamada; Yasufumi Sawada; Tatsuji Iga
Biological & Pharmaceutical Bulletin | 1996
Yukiko Nakajima; Koujirou Yamamoto; Shuji Shimada; Hajime Kotaki; Yasufumi Sawada; Tatsuji Iga
Drug Metabolism and Pharmacokinetics | 2003
Kisho Shiseki; Masaya Itoda; Yoshiro Saito; Yukiko Nakajima; Keiko Maekawa; Hideo Kimura; Yu-ichi Goto; Osamu Saitoh; Masaaki Katoh; Teiichi Ohnuma; Mitsuru Kawai; Kenji Sugai; Taisuke Ohtsuki; Chieko Suzuki; Narihiro Minami; Shogo Ozawa; Jun-ichi Sawada